drugset
drugset / Trial / NCT01072383

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01072383 ↗

Phase 2 Completed 49 enrolled Biotest
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.

Timeline

Start
2010-02
Primary completion
2011-06
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BT061 Monoclonal antibody — Intravenous

Indications

psoriasis